Enjoy complimentary customisation on priority with our Enterprise License!
The global liver cirrhosis therapeutics market size is estimated to grow by USD 1.94 billion at a CAGR of 5.58% between 2023 and 2028. The market is experiencing significant growth due to the rising incidence of liver cancer. According to recent medical research, liver cancer is becoming increasingly prevalent, with risk factors such as alcohol consumption, obesity, and viral hepatitis contributing to its spread. In response to this public health concern, advancements in medical research are leading to the development of innovative therapeutic solutions. Pharmaceutical companies and healthcare providers are collaborating more closely than ever before to bring these new treatments to market. These collaborations are fueled by the recognition that effective liver cirrhosis therapies have the potential to save countless lives and reduce healthcare costs associated with liver disease. As a result, the market is poised for robust growth in the coming years. In summary, the market is experiencing significant expansion due to the increasing incidence of liver cancer and the resulting demand for effective treatments. Advancements in medical research and collaborations between pharmaceutical companies and healthcare providers are driving this growth, as innovative therapeutic solutions are developed to address the public health challenge posed by liver cirrhosis.
To learn more about this report, Request Free Sample
The market share growth by the oral segment will be significant during the forecast period. The oral type emerges as the market leader in the dynamic global market, indicating a paradigm shift in therapeutic approaches. Oral medications are becoming increasingly popular because of their patient-friendly qualities.
Get a glance at the market contribution of various segments Download PDF Sample
The oral segment was the largest and was valued at USD 3.81 billion in 2018. One example of an innovative drug is Obet cholic acid. Oral therapies such as medicines for non-alcoholic fatty liver disease (NAFLD) and antifibrotic medications are in high demand as people prioritize convenience and ease of administration. This development is being driven by industry efforts to improve treatment adherence in addition to patient preferences. The development of novel oral formulations that target particular pathways in the evolution of liver cirrhosis highlights the effectiveness and promise of this therapeutic strategy. This market scenario highlights an optimistic tendency and positions oral treatments as a key segment in the evolving market in focus. This, in turn, will drive the growth of global market during the forecast period.
The global market is expected to be dominated by hospitals as the primary distribution channel. Hospitals' pivotal role in patient care and treatment is driving this expansion. Hospitals enable easy access by providing a wide range of medical services under one roof. Prominent medical centres such as Cleveland Clinic and Mayo Clinic are noteworthy instances of the way they use their expertise to improve liver cirrhosis therapeutics. Hospitals remain a primary distribution channel, as evidenced by the faith that patients have in hospital-based healthcare. Such factors are expected to increase the adoption of hospitals as a distribution channel and hence drive the growth of the market during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The regional market is expanding rapidly, propelled by factors such as the increased prevalence of liver disorders, growing public awareness, and sophisticated healthcare infrastructure. Over 630,000 persons were diagnosed with liver cirrhosis in the US alone in 2020, as the condition's incidence has been rising gradually. The increasing load has encouraged pharmaceutical companies to spend on R and D, which has resulted in the release of novel treatments. Drugs like Obet cholic acid, which have the approval of the FDA to treat liver fibrosis brought on by non-alcoholic steatohepatitis (NASH), are witnessing a sharp increase in use in the regional market.
In addition, the regional market's growth is further aided by the existence of major players like Gilead Sciences and Intercept Pharmaceuticals, as well as tactical alliances between drug manufacturers and healthcare providers. The region's dedication to developing medicinal solutions and meeting the growing healthcare needs related to liver cirrhosis is demonstrated by the rise of the market in focus, which in turn is expected to drive the growth of the regional market during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 18 market companies, including:
Alnylam Pharmaceuticals Inc. - The company offers liver cirrhosis therapeutics such as siRNA-based targeted therapy to restore functional liver cells in patients with end-stage liver diseases.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
In the dynamic field of liver disease research, the market continues to evolve, driven by advancements in various areas, including AASLD (American Association for the Study of Liver Diseases) conferences and Frontiers in Medicine. Systemic inflammation plays a significant role in liver cirrhosis, with Primary Biliary Cholangitis , Hepatitis B (HBV) and Hepatitis C (HCV) being major contributors to chronic liver disease. Molecular hepatology and hepatology journals publish the latest findings on these conditions, shedding light on the mechanisms of liver damage and potential therapeutic targets. ILTS (International Liver Transplantation Society), ILDLT (International Liver Donor Liver Transplant Registry), and LTSI (Liver Transplantation Study Group of the International Liver Association) collaborate on research activities, focusing on antiviral drugs like Mavyret, Zepatier, and Vosevi. These drugs have shown promising results in treating HBV and HCV, contributing to the reduction of hepatocellular carcinoma (HCC) risk.
BMC Infectious Diseases and other research platforms publish studies on novel drugs and lifestyle interventions for liver cirrhosis. Cystic fibrosis, a genetic disorder, can also lead to liver cirrhosis, further expanding the scope of research in this area. The Liver Cirrhosis Therapeutics Market is poised for growth as researchers and pharmaceutical companies continue to explore new treatments and improve existing ones. Our researchers analyzed the data with 2023 as the base year, along with the trends, and challenges.
The trend towards personalized medicine is an emerging trend shaping the market growth. Customizing treatment plans based on unique patient characteristics, such as genetic composition, liver function, and medication response, is a trend toward personalized medicine in the global market. This strategy seeks to maximize therapeutic results, reduce side effects, and improve patients' general quality of life. Genetic profiling, for example, can pinpoint precise biomarkers that impact drug metabolism, making it possible to prescribe the most effective drugs for a certain patient. With a more focused and specific approach to therapy, this trend represents a move away from a one-size-fits-all strategy and towards better patient outcomes and higher therapeutic efficacy.
Moreover, the global market is undergoing a paradigm change towards more personalized and patient-centred therapy as precision medicine continues to progress. Hence, the trend toward personalized liver cirrhosis therapeutics is expected to drive the growth of the market during the forecast period.
The high cost of liver cirrhosis therapeutics is a significant challenge hindering market growth. A major challenge in the global market is the high cost, which prevents certain patient groups from accessing them. Immunosuppressants and antiviral medications for hepatitis may need extensive courses, which adds significantly to the cost of care. Furthermore, sophisticated treatments such as liver transplantation, which may be a curative measure for end-stage cirrhosis, come with extremely high expenses associated with the surgery, the recovery period following the procedure, and the lifetime immunosuppressive drugs. People who live in areas with minimal healthcare resources or who have limited healthcare coverage are disproportionately affected by this financial hardship.
For instance, the cost barrier keeps many people from getting timely and effective liver cirrhosis therapies in underdeveloped nations, where affordability is a major concern. This exacerbates health disparities globally. Hence, the high cost is expected to be a constraint for the wide-scale adoption, which, in turn, will hinder the growth of the market during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
In the realm of hepatology, addressing liver disease treatment is paramount, particularly in combating cirrhosis medications. As fibrosis progression leads to hepatic decompensation and liver failure management, effective interventions are crucial. The market for human liver health solutions, including Ursodeoxycholic acid , hepatoprotective agents and antifibrotic therapies, is witnessing significant growth, driven by escalating cases of alcoholic liver disease and viral hepatitis treatment needs. Market research and growth indicate a promising trajectory for ascites treatment and managing portal hypertension and hepatic encephalopathy. Innovative approaches to liver regeneration offer hope for patients. Market forecasting underscores the importance of strategic planning in this evolving landscape, where advancements in liver damage therapeutics continue to emerge, shaping the future.
In the dynamic and rapidly changing healthcare landscape, the market holds significant importance due to the increasing prevalence of liver cirrhosis, a chronic and often progressive condition that can lead to serious complications and even death. Factors contributing to the disease include clinical liver diseases such as chronic hepatitis, alcohol abuse, and infections, including syphilis. The geriatric population is particularly vulnerable, as they are more likely to develop liver cirrhosis due to age-related declines in liver function and the presence of underlying conditions. Despite the urgent need for effective treatments, market restraints such as the high investment required for research and development, side effects of medications, and the potential for complications from antibiotics and infections, pose challenges. However, the development of better treatment methods, including liver transplants, home care, and awareness programs, offers hope for those affected by liver cirrhosis.
You may also be interested in:
Liver Cancer Drugs Market - Liver Cancer Drugs Market by Type and Geography - Forecast and Analysis
Human Liver Models Market - Human Liver Models Market by Type and Geography - Forecast and Analysis
Ursodeoxycholic Acid Market - Ursodeoxycholic Acid Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, China, Canada, India - Size and Forecast
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024 to 2028, as well as historical data from 2018 to 2023 for the following segments
Market Scope |
|
Report Coverage |
Details |
Page number |
154 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.58% |
Market Growth 2024-2028 |
USD 1.94 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
4.57 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 41% |
Key countries |
US, Germany, UK, Japan, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, CSL Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Gwo Xi Stem Cell Applied Technology, Johnson and Johnson, Kezar Life Sciences Inc., Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Protagonist Therapeutics Inc., and Tessera Therapeutics |
Market dynamics |
Parent market analysis, market growth and forecasting inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the market forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.